Home
Untitled - 日本メジフィジックス
Contents
1.
2. hot Spot
3. 4D PET CT 4c o 5 I 1 FDG 6496 529 6 769 2 FDG
4. 2 2 1 mSv mSv
5. FDG PET PET CT 1 Lee JH et al The role of radiotracer imaging in the diagnosis and management of patients with breast cancer part l overview detection and staging J Nucl Med 2009 50 4 569 581 2 Lee JH et al The role of radiotracer imaging in the diagnosis and management of patients with breast cancer part 2 response to therapy other indications and future directions J Nucl Med 2009 50 5 738 748 3 Mavi A et al Dual time point F FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes J Nucl Med 2006 47 9 1440 1448 4 Groheux D et al The yield of PF FDG PET CT in patients with clinical stage IIA
6. 3c _ PET CT 3d MRI 40 4313188483 dO Bus U V EIE 0 PET CT FDG 299 2MBq 4 21MBq Kg 82mg mL MIP 4a FDG 2 PET CT 4b 4c SUVmax E 9 8 D 11 8 SUVmax E 6 3 D 8 4 GUVmax E 13 3 D 4a MIP 4c PET C 14 8
7. Beo 7 I uaUTAem NEAL MIKROA QNSE J7 7Jb9PSICd ess cDm TUe Aie F PET
8. FDG PET CT 2 1 1 0mm 10 193 17 22 28 37mm 2 1 1 5 30kBq mL 10mm EE 1
9. MHRHI PET MRI T PET E PrETcds5IEESTRUJEZUT S ust OFDORUR k
10. 2 2 1 NECpatient NECdensity NECpatient NEC noise equivalent count OSEM EE n n OSEM PSF 8 OSEM PSF TOF O 10 13 197 o 28 ELS ROI 37 mm NECdensity NECpatient gt 1 3 NECaensity O 2 c UC bis 2 2 2 SNR 3cm ROI 3 9 SNR ROI
11. eCT PET SUV 6 4 3 6 3 6 1 7 5 0 2 3 2 5 1 3 SUV 1 Bares R et al F 18 fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer Radiology 1994 192 79 86 2 Ho CL et al FDG PET evaluation of indeterminate pancreatic masses J Comput Assist Tomogr 1996 20 363 369 3 Pery C et al Role and limitations of F FDG positron emission tomography PET in the management of patients with pancreatic lesio
12. FDG metabolic stunning PET 2 3 Standardized uptake value SUV
13. 3696 509 4 PET 3 18 HOPET 3 PET 30 18 sS PET 1 4 30 SUVmax 182 4
14. 3min SNR 96 risp FDG SNR PET Daily QC mis PET CTOdaily QC 1 Townsend DW Dual Modality Imaging Combining Anatomy and Function J Nucl Med 2008 49 938 955 2 004 41 1 3 FDG PET GO005 A2 4 1 22 4 FDG PET 2005 CO005 A2 9 1 26 5 National Electrical Manufacturers Association NEMA Standards Publication NU 2 200 7 Performance Measurements of Positron Emission Tomographs Rosslyn VA National Electrical Manufacturers Association 2007 6 FDG PET
15. a PET 1 3 FDG PET CT RI
16. S006 4 3 9 ICRP Publication60 1990 007 He 100mSV 5 800 1 4 1 5 50mSv 4 1 1 iex SmSv 9 4 1 1 10 1 1 1 3 1mSv _ 150mSV 4 1 1 EU ERE 300m
17. FDG PE PET CT PET FDG PET PET 2012 4 FE
18. MRI MRI FDG 5258 SUV MHRHI FDG 1 3 Mucinous borderline tumor E Bo E RSS 0D RE COSE ERV A 7 SRODD FOCE PET PETHS serous cystadenocarcinoma Mucinous serou
19. PET CT FDG FDG FDG PELO PET FDC FDG
20. c PET EL a PET 1
21. daily QC PET 6 E CTX X CT SD 3 2 PET CT CT PET CT CT 3 3 PET Vid 1min emin
22. capsular retraction PET 4a PET CT 1 PET CT j4db PET CT 4c PET CT a a Co OU Z0 1 CEA80 1ng mL 5 0ng mL CT C 5a FDG 1 5D S8 18mm SUVmax 5 9 2 SUVmax 7 3 PE
23. PET PET X PET PET PET CT X CT PE PET
24. RI HI 3 1 1 mSv 2 1 GmSv 3 3 1 3mSv G E Oo 00 CPU c r3 O C SPECT N E Eee d4 J25 EX Y EEM T tH EV TIJ V 9 8550 SV 3 PET CT H RI
25. SA ER EI CDU MEUNU En Loi IVR eerie 1 5mSv 1 1 mSv
26. PET RI RI RI RI 4 4 a b
27. CCF cross calibration factor cps mL Bag mL SUV standardized uptake value PET 7 F G0cm PET CT PET PET ROI PET
28. PET FDG FDG PET 3 PF PET 1 3 4 1 2 3 PET AUEEMMDXxHER XZ7DZ77 2l 348 FDG PE 1 3
29. PET RI 0 AE RI c ZZ DTE RI E J E k T3 RI EIIEZ E1052 237129 VEDI Cc LN PET
30. 3 PET CT CT CT PET CT
31. PET CT PET CT inii UA gm PET CT PET Dum Wal Bn E ges RB JE eer CT k 4 PET National Electrical Manufactures Association NEMA JIRA PE
32. DLBCL PET ec PET CT Gd PET GD CT ee PET r1 A HIT pa ID NIELSEN 1 iI p In A LL Li uni yu ls aN y 7 jl ad y Ja m mmy VCI EWRLIE E 3 A e LA b nu lr i LL E CLAN ID A uud 1 IN PE RN PAS e S IP S zd 30 CT MRI 3a TOIR MAREEN PET CT PET
33. E16 5a CT 5D PET CT TOF PET 5mm 5 mm SUVmax 1 8 6a CRT PET CT 80 6b CRT CT Esttfg UU 777 V8 1069 SUVmax 3 2 8mm CRT PET 3 me FDG 18 7
34. FDG FDG FDG 5 FDG 40 60 FDG 40 60 8 8 FDG m id FDG I euam Xr EORR DOE Mk mene pee me io ee e 6 LES FDG 30 5 H CO MESHA eO 5 1 3 ad FDG FDG FDG FDG
35. 1 EE ERU ER S Gamut of FDG PET 2012 49 357 389 2 Keyes JW Jr SUV Standard uptake or silly useless value J Nucl Med 1995 36 18936 1839 3 1998 PET URSUS PET
36. FDG FDG 40 60 6 FDG 12 FDG FDG
37. ATLL RA TARAA U V HE OWE slL PH ATLL PET ATLL 6a 6b ATLL HTLV 1 T 1 6a PET HTLV 1 PET slL 2RH
38. CA72 A 6b 6c 12 0 PET CT FDC e PET MIP 6a Cla 7c ER ES hot spot AKRE 4 2 hot spot 6D PET 6c 6a MIP 6b PET CT 6c PET CT 0 3 serous papillary cystadenocarcinoma DT3NOMO
39. MIP maximum intensity projection MIP X CT MIP PET CT CT
40. Ga 67 18 509 PET Ga 67 PET 2012 4 18 5g i 154 PET k FDG
41. d PET 7e PET 70 PET FDG 8b PET CT PET CT CT CT 8a 8a CT BD PET o p PET CT 84 9696 73 10096 PPV 81 10096 NPV 52899 MMG US
42. 6b PET CT R PETI KSR HESS DR i FERMI d D TREHBED SEA OD CHRE BTPMBE ESTER FABBEN CaoS S e TICRBESRESIS Bul dx O82 WIBED SEO FIBERO DAAE Ek O SZ TRES 1 BESTE SUV4 8 T 1 5cm PET CT C mucinous adenocarcinoma SUVmax 4 MRCP
43. PET EREC CODBBICXERE S OREU YV VE CE EZ FDGC 1 FDG FDG FT reremo tao m ED EHEDOi amp sId OD fBfHBJICsZHID EXEC COSR
44. 4 1 FDG PET 18 5g FDG 15 50 kg FDG 7 FDG 3D 111 259MBq 5MBaq kg D FDG
45. PET OT PET C misregistration CT PE overuse FDG PET C58 HTZ CUVOcRHEERIC SERSO BED Tv PET
46. 3 PET 10a PET 10D 10 PET 10c HRCT 70 30 G3cm SGM2 PET CT CRT CEU PET A PET PET
47. mass effectis 1 2009 2009 p52 53 2 Sun L et al Metabolic restaging of hepatocellular carcinoma using whole body F FDG PET CT World J Hepatol 2009 31 90 97 3 HBA ft PET CT 6012 109 1878 1884 4 18 2004 2005 6010 51 460 484 5 Kim YJ et al Usefulness of F FDG PET in intrahepatic cholangiocarcinoma Eur J Nucl Med Mol Imaging 2003 3C 1467 1472 6 Chung YE et al Varying appearances of cholangiocarcinoma radiologic pathologic correlation Radiographics 2009 29 683 700 2010 8 Minagawa M et al Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer long term results Ann Surg 2000 231 487 499 9 Wiering B et al The impact of fluor 18 deoxyglucose positron emission tomography in the mana
48. MRHCP Rokitansky Aschoff sinus 33X55mm PET CT 1a MIP ld PET CT PET OIH TESTS 64 l 3 CT PET CT SUVmax 4 40 SUV 2a d CT 15mm
49. 1 5 FDG 1 6 FDG 1 7 PET 28 1 FDG PET PET
50. 4 1 IVR PET
51. FDG PSA PET MRI 4 PET PSA PSA
52. FDG IL TOBA RREI RONIE PET CT FDG FDG Responder 729 5496 Non reSDOnder 949 7996 MMG US MRI PET CT
53. FDG FDG PET Beer REC RA Hodgkin s lymphorna HL Non Hodgkin s lymphoma NHL NHL Aggressive lymphoma Indolent lymphoma HL B DLBCL FDG FDG avid FDG Follicular Iymphoma FL MCL FDG vid Marginal zone lymphoma MALT Ilymphoma FDG FL MCL FDG avid
54. 2006 Fh UA _ Eu SUV SUVmax FDG Iwai K et al Racial difference in cardiac sarcoidosis incidence Observed at autopsy Sarcoidosis 1994 1 1 26 31 2 Silverman KJ et al Cardiac sarcoid a clinicopathologic study of 84 unselected patients with systemic sarcoidosis Circulation 1978 58 1204 121 I 3 Iwai K et al Pathological studies on sarcoidosis autopsy l Epidemiological features of 320 cases in Japan Acta Pathol Jpn 1993 43 372 376 4
55. 5 Gamut of FDG PET 5mm Cm 1mm FDG
56. 10 3 4 1 SU SUE 3 BEHIA 4 2013 4 1 me PET PET CT FDG
57. G4 679 93 100 Ga 6 18 509 1009 MRI 7 5 100 5 789 MRI 1 ICD MRI 1 CT 3 1 2 3 6 2
58. PET FRAR CDO 1 PET 1998 54 1141 1148 2 EK PET PET CT R 2010 65 eale 222 3 Yasuda S et al Preliminary study comparing diffuse gastric FDG uptake and gastritis Tokai J Exp Clin Med 2008 33 138 142 4 Lordick F et al PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction the MUNICON phase ll trial Lancet Oncol 2007 8 797 805 5 Wahl RL et al From RECIST to PERCIST evolving considerations for PET response criteria in solid tumors J Nucl Med 2009 50 1228 15085 1a tub SM NO 0 53 PET CT tub2 1b c BUPSRIESUJERM D 1129TU PET 1d G0 20mm 0 lla 1a lc PET CT ld
59. 65kBq mL 1 10mm NECphantom 10mm Ty FERCBGOROIZ min 6min ROI 10mm 2 QH 10mm 96 N10mm 1 5 NECphantom gt 10 4 Mcounts N10mm 6 6 QH 10mm N10mm gt 1 9 96 3 2 1 2 2 65kBq mL 1 10 2min 7 min N10mm 3min 4min 5min 8min 9min 1 Omin QH 10mm N 1 Omm NECphantom 80 I 5 30kBq ml 704 2 65kBa ml NE Mcounts 4 6 8 min Fic 5 30OkBa ml m G 2 65kBa ml E 4
60. PET CT 60 b d 2a MIP 110211 Gd MIP Ge CT GD CT PET FDG 60 Gc _ PET CT Gf PET CT SAAR 60 1 SCC 1 7 4 7 9 7
61. 4mm 10mm PET PET 1096 CT 3 10mm BAC PET cm PET CT PET CT
62. SI bronchioalveolar carcinoma G 6 Pase FDG
63. CT 3b 3c 3d 3a CT MHI 3D PET 3d B Precursor B lymphoblastic lymphoma B LBL FDG 3e PET CT 3e PET 60
64. PET CT 10 PE T ET FDG PET T3EB AMBAS SHE LIRE ERIR BuU DER BT BARBA F3 Bats B56 BA KB DESDE RDZ O
65. PET 6b PET CT FDG 2012 X MN meeeorE conum 7 096 E AE E T a PET PET PET PE XX CT PET FDG FDG
66. PET CT SUVmax 8 8 gt 10 9 5 n Ga MIP GD CT Gc PET CT PET 67 1 Nito CT CA19 9 100 CT MRI 3a c PET CT MRI PET 3a MIP 3b CT 3C PET CT 44 8 CT
67. VO meg PET PET AEP FAS 1 PE PET CT 1 FDG 2
68. PET CMXBA in patients with colorectal carcinoma J Nucl Med 2003 Nov 44 maena et al Combined CT colonography and F FDG PET of aD 7971803 colon polyps potential technique for selective detection of cancer 4 Frankel TL et al Preoperative imaging for hepatic resection of BELT and precancerous lesions AJR Am J Roentgenol 2007 Jan 188 1 colorectal cancer metastasis J Gastrointest Oncol 2012 Mar 3 130 138 19 11 18 2 Israel O et al PET CT detection of unexpected gastrointestinal 5 Denecke T et al Comparison of CT MRI and FDG PET in response foci of F FDG uptake incidence localization patterns and clinical prediction of patients with locally advanced rectal cancer after significance J Nucl Med 2005 May 46 5 758 762 multimodal preoperative therapy is there a benefit in using 3 Cohade C et al Direct comparison of F FDG PET and PET CT functional imaging Eur Radiol 2005 Aug 15 8 1658 1668 0 mmucinous adenocarcinoma 231 PE
69. 3 1 796 6896 19882 199
70. 94 100 979 PET PET EAC ESCC 92 996 EAC 496 Glut 1 ESCC EAC PET
71. RI ig PET E RESDA EA HRI HI 3 4 6 PET CT
72. 1 FDG FDG PET PET C CT PET CT 67 87 5 5 97 2 FDG PET 5 97 100 3 PET
73. 7 8 9 10 PET CT 1 SPECT 1 6 13 2 RI x PET CT 1 SPECT 1 50mx16 3m 326m2
74. CT 2e MRCP 20X8X15mm eb PETEK ee CT 2a MIP Gd PET CT PET CT 1 BEA MIBESTR 84 CT PET CT 2 SUVmax 2 89 GSUVmax 3 86 UR 3a d 3 33m CT E EBED EDH STUSS IS E Cub BBSSESODREI b U 4 XEJECOSR BB gZ Dd oOTUBZREX O5 Th CTOd Dol EC 3e
75. a D c Gallium 67 d 4 MRI PET x PET CT PET PET 1 1009 G38 1009 8996 Z7896
76. 01 7 8 IMHT 68 8G y 01 6 PET CT SUVmax 18 89 FDG 4a G012 10 PET C CT FDG 4b MIP PET CT PET CT 4b PET CT ODORE UIE 000 005 1 5 010 PET CT 5a KIHEI IR 111MBqg 4 5b
77. FDG 3b PET CT _ ZUINU PETORHE C En GDZRAESESBTPAIRB ES Ten Z0 9 B 1 C CA198 9 542 1U mL 37U mL CEA5 3ng mL 5 0ng mL PET CT SUVmax 3 1 3 3 4a 1 PET T SUVmax 3 6 4D 2 GUVmax 6 1 4c Reg PET CT adenocarcinoma MRI
78. ba PET CT 3 GBaiz Slc d e WBSETEOR 711 1cb Ia O Ame 5c PET CT PET CT tracer dose 5D I 111MBq 5c 311 3 7GBq PET LE FDG PET PET CT PET CT 909
79. PET 2 FDG 3 FDG PET FDG 4 FDG
80. FDG 40 PET PET MIP 1a PET CT 1c 1 9 NO i i ii 1a MIP iana 1b CT te 1c PET CT 50 PET 60 2a c 110 d f FDG
81. 4 1 5 E 1 a b C Gallium 67 citrate d 5096 2 a Q b UD ERR C thallium 201 chloride technetium 99m methoxy isobutyl isonitrile technetium 99m tetrofosmin d Gadolinium MRI 8 4 5 DS ST ETEL 6
82. FBP PET 1 5 1 6 NEMA NU2 2001 Standard 700mm 100cm 60 1bed 10 13 17 2mm 8 9 mm 7S7
83. FDG PET PET CT PET PET CT
84. PET CA155 PET 60 7a 120 7D hot spots PET CT 7c 7a PET 60 7b PET 120 3 1 double J 4 PET CT FDG E 7c CT PET CT PETIe dva Es EDD Birds EZ AIT
85. 4e PET CT 2CT PET CT 3 C PET CT 4a MIP 4D PET 4e CT mm 1 FDG e 9096 FDG 909 8096 1
86. S rocosme PET CT PET Body mass index BMD PET NECpatient gt 13 NECdensity gt 0 SNR gt 10 PE PE CT o PET CT D FDG PET 2005 42 4 FDG PET CT
87. 2 FWHM 1 10 FWTM full width at tenth maximum 1 2 B00mm 700mm PET 1 3 5 1 4 600mm
88. 4c CT 4f PETER EFH 60 PET 5a 5b 5c Intravascular Iymphomatosis 5d a 4 i 5a PET fliki B BB KE B BT TSBSIRC ICA UG PET PET 5c _ PET CT PET T
89. 1 I PET II 3 IV PET 1 V PET a 2 1 9 DIS 1 PET PET SI a EH d J
90. ALEAR VE ERARA YVE A RARS U FDG 3D c d 009 5 68 8Gy IMRT PET CT 3a PET CT 3f CT PET CT 3j 1 PET CT U FDG 3e f g 3h 1 9 201 1 CT MRI 01 1 PET CT DERTTE SUVmax 1 7 06 3j 3h FDG _ ZUANU PETORITEC En IMRT 68 201
91. 2 PE PET i PK me PET 1 PET BAHH OESSTSRODSS 1 1 PET PET PET 1 2
92. FDG 4 PET FDG FDG FDG FDG PET FDG PET G ESRBOFDOPETBRO 1 ft Gamut of FDG PET 6012 A9 357 389 PET EI N FDG PE 8G008 4 BESSSESEImOFDGD
93. Grade3 L L2 P 3d MIP i j HE PET 70O Grade3 pT 1 PET CT CT 4a PET CT 4D RRE 4a CT 4c
94. PET CT lc PET 30 T 2a 8b Ez SEUVETNS DLBCL PET C CT IV 2c 2d H CHOP CR 2e PET
95. 5 PET FDG 6 PE PET
96. 1992 4 19983 23 24 5 Patel MR et al Detection of myocardial damage in patients with sarcoidosis Circulation 2009 120 1969 1977 6 Youssef G et al The use of F FDG PET in the diagnosis of cardiac sarcoidosis a systematic review and metaanalysis including the Ontario experience J Nucl Med 20128 53 241 248 7 Uemura A et al Histologic diagnostic rate of cardiac sarcoidosis evaluation of endomyocardial biopsies Am Heart J 1999 138 299 302 8 Doughan AR et al Cardiac sarcoidosis Heart 2006 92 282 288 9 Langah R et al Effectiveness of prolonged fasting 18F FDG PET CT in the detection of cardiac sarcoidosis J Nucl Cardiol 2009 16 801 810 10 Ishimaru S et al Focal uptake on PF fluoro 2 deoxyglucose positron emission tomography images indicates cardiac involvement of sarcoidosis Eur Heart J 2005 26 1538 1543 11 Cheng VY et al Impact of carbohydrate restriction with and without fatty acid loading on myocardial F FDG uptake during PET a randomized controlled trial J Nucl Cardiol 2010 1 7 286 291 12 Ohira H et al F Fluoro 2 deoxyglucose positron emission tomography in cardiac sarcoidosis Eur J Nucl Med Mol Imaging 2011 38 1773 1783 13
97. BETHAN KE CIcbKESICHRTETEBASD ABRE MIP T1a PET CT 1b PET CT 1c SUVmax 15 9 N te 1D PET CT 1a MIP 1d 1d Zn RHI HE 1e Grade3 FDG lc PET CT TE e 4 m w 5 d 3 T R E CU an x 1e HE PET OBSE 70
98. 2006 O007 27 89 102 14 28 15 24 2008 1 1 60 10 1 e PET PET CT FDG 30mg 1 PET 30 SUVmax 12 8 3 2 3 CT
99. PET C PET OT 360 6 196 80 PPV 6296 NPV 7 9 2cm 1 2 0 30 PET CT SNB PET CT SNB PET CT
100. CT PET 90 100 PET CT 5 409 PET 70 10096 PET PET PET PET FDG 3 6 IWC 8 12 PET 4 PET HL PET
101. 1 Oyama N et al The increased accumulation of F fluorodeoxyglucose in untreated prostate cancer Jpn J Clin Oncol 1999 Dec 29 18 623 629 2 Minamimoto R et al The potential of FDG PET CT for detecting prostate cancer in patients with an elevated serum PSA level Ann Nucl Med 201 1 25 1 81 27 3 Shreve PD et al Metastatic prostate cancer initial findings of PET with 2 deoxy 2 F 18 fluoro D glucose Radiology 1996 199 751 756 4 Sch der H et al 2 F fluoro 2 deoxyglucose positron emission tomography for the detection of disease in patients with prostate specific antigen relapse after radical prostatectomy Clin Cancer Res 2005 11 13 4761 4769 5 Chang CH et al Detecting metastatic pelvic lymph nodes by 1 8F 2 deoxyglucose positron emission tomography in patients with prostate specific antigen relapse after treatment for localized prostate cancer Urol Int 2003 70 4 31 1 315 6 Yeh SD et al Detection of bony metastases of androgen independent prostate cancer by PET FDG Nucl Med Biol 1996 23 0 093 697 7 Morris MJ et al Fluorinated deoxyglucose positron emission tomography imaging in progressive metastatic prostate cancer Urology 2002 59 913 918 8 Jadvar H FDG PET in prostate cancer PET Clin 2009 4 2 155 161 9 Salminen E et al Investigations with FDG PET scanning in prostate cancer show limited value for clinical practice A
102. 9 PET CT 3a MIP 3b PET 3c CT me ed p 8s M 3e CT 3d PET CT PET 7 79 30 CA19 9 4000U mL CT SUVmax 5 19 CT 4a d
103. FDG FDG SUV 5 4 M
104. PET 2 SUV 6 PET PET CT SUV SUV SUV tubular type cholangiocarcinoma mucinous adenocarcinoma PET ERCP MHRI O 3
105. a b PE SUVmax 5 c CT FDG d PET CT MHRI PET Sun L IVR PET CT 89 59 83 396 88 09 Gc _ PET CT led CT ee ZORN HIE AHAHA CILI CT 3a ERCP
106. 1 SUV FDG SUV FDG 4 SUV cut off
107. CT PET one stop Shopping PE PET PET 1 012 2 Lindell RM et al Lung cancer screening experience a retrospective review of PET in 22 non small cell lung carcinomas detected on screening chest CT in a high risk population AJR Am J Roentgenol 2005 185 126 131 3 Cronin P et al Solitary pulmonary nodules meta analytic comparison of cross sectional imaging modalities for diagnosis of malignancy Radiology 2008 246 772 782 4 Nomori H et al The size of metastatic foci and lymph nodes yielding fa
108. FDG FDG FDG FDG FDG FDG CT PET PET CT PET PET
109. 609 PET PET CT MHRI PET FDG
110. PET MRI PET CT CT PET CT rs PET EO PET 3 5mm i a 10mm
111. FDG 3c PET CT PET 60 CA19 9 67 PET PET MIP 4a CT 4D PET 4c PET FDG PET
112. PET PET FDG 3a c 5 5 PET 3 FDG 3a MIP GD CT PET FDG ie o FM m ome dei PET 1 1 ex Use DIESES PRTA RRE PET PET
113. 8c Gd SPECT PET CT FDG 2e CT 1 PET CT Pc MIP ee SPECT fY a a Co OU 56 008 1 0098 PET CT FDG GUVmax 193 98 3a
114. PET CT CT PET 01 4 2 Kato H et al The incremental effect of positron emission tomography on diagnostic accuraoy in the initial staging of esophageal carcinoma Cancer 2005 103 148 156 3 Nakajo M et al Clinical significance of primary lesion FDG uptake for choice between oesophagectomy and endoscopic submucosal dissection for resectable oesophageal squamous cell carcinomas Eur Radiol 201 1 21 29396 2407 4 Imperiale A et al Does the association of F FDG uptake intensity and lesion topography reveal histological phenotype and tumor differentiation in esophageal cancer Hell J Nucl Med 201 1l 14 239 242 5 Omloo JM et al FDG PET parameters as prognostic factor in esophageal cancer patients
115. F NU 00 1 JESRA X 0073 JESRAX 0073 A2005 PET CT PET 1 PET PE T ROI region of interest PET PET 1 1 FWHM full width at half maximum 1 3 FBP
116. FDG FDG 4d PET CT CT 4e PHX DAEDT PETC ERE 7 JN zu cade a 4b CT ki f i Fe T1 ms y ud An H 1 h e jV t i 4a MIP 4c PET PET CT FDG
117. PET CT Elba MIP 5b MIP 1 5 PET 5b 5c FDG 4 PET CT MIP 5d 5e FDG SUVmax E 4 2 PET CT FDG 5d MIP 4 be PET CT 4 LL Di 2 3 3 I BER XR PET
118. ACE Gallium 67 citrate CD4 CD8 CA domi 2 3 Fluorine 18 fluorodeoxyglucose PET Q 6 1 4
119. SNR gt 10 B5 n ET CT B 2 PET CTZi amp OD ERE EO ERa C al B LC FRE PET PET CT ROI
120. 9296 CR 24 596 CR DLBCL 4 PET 8296 event free 2596 event free SeCOnd line PET PET CT limitation 1 Paes FM et al FDG PET CT of extranodal involvement in non Hodgkin lymphoma and Hodgkin disease Radiographics 20 10 30 269 291 2 Kwee TC et al Imaging in staging of malignant lymphoma a s
121. FDG FDC FDG FDG FDC FDG SUV standardized uptake value PET
122. PET CT CT CT MRI 1 1 009 12 2 MRI KEY BOOK 2004 3 Chung HH et al Preoperative F FDG PET CT predicts recurrence in patients with epithelial ovarian cancer J Gynecol Oncol 2012 23 28 34 4 Lyer VR et al MRI CT and PET CT for ovarian cancer detection and adnexal
123. aM PET PET PET CT A PET CT C PET 40 1 0 GMBq lbed 90 BMI BMI ee e4 23 eb 90 sec bed XBMI sec bed BMI 15 18 X3 MBg kg x kg MBq Se esa eme enu je Hox ZS 128 AS sa 0 6 0 68 0 75 OO 8 8 5 PET CT ke 110 a 100 4 e e 904 e e e e 80 4 e e e 70 MES e M e e e e e ME x o e e e 50 4 o S E e amp 40 x Se e e e 9 e 30 4MBa kg 20 o 9 I bed 3 0min e bed 2 5min 10 9 bed 2 0min 0 T T T T T T T T 1 80 60 40 20 0 20 40 60 80 100 mm 307 270 238 210 185 163 144 127 e 98 MBq i au n d Los 22 7703 99s 72kg 90kg 108kg 20050 970MBg 68kg abkg 102kg 50558 MESZ 64kg 79kg 95kg 407 F 238MB 6Okg 75kg 90kg 20579 R SPOZMBS 56kg Okg 84kg 2207590 EB 52kg 66kg 7
124. 1b MIP PET OE LED WR SEDES CWI CFK I SED IOSERESOOPET CTC Ga ChB AVS PET CT FDG 2D c Ca GlD MIP Gd 35xX25mm 0 tub 1 gt tub SM NO0 0 47 Coole Gc PET CT Bd re DIA ELT ar PET CT por gt porl gt sig Ka b B FDG 3c 3d 90xX80mm El3a MIP 3C 3b PET CT 3d PET
125. 3 2 3 1 FDG 110 3 FDG 2SmL 18 185MBqg esl HEN a zn E muon A d A PEDR Up FDG SNT Em CAFE NTS COBIAN FILIA DK aaO Ice5Ic AEDES 20MM TCE D 7kg 3 oeom 1 74MBqg 370MBq 2 4 74MBq FDG 4 FDG fluorodeoxyglucose
126. PET 4a d SUVmax 4 1 4c CT 4b MIP GEER 4d PET CTBi amp PET PET cds E SEDEM RERO T me Tahae bll RAKD k OBM AORE PET MRHI PET PET PET C CT 90 93 81 100 87 96 91 10096 83 100 9 97 5
127. 60 PET CT 1Ded 5 10 i d PET is 60 R FDG 50 kg E 3MBg kg EAE PET CT PET PET 1992 006 1 gt
128. PET 71 93 CT 2 91 129 PET 4196 38 G00 PET CT MD CT EUS PET CT 1196 Wu UL Wc RF ue 6 PET CT 01 4 T1DSM FDG PET 7a MIP 7c PET CT EA 70 PET CT SUVmax 8 1 PET CT SUVmax 9 9 CB
129. CT FDG PE SUV SUV PET PET 1 5cm
130. 1 4 4a CA19 9 509 1 Clear cell adenocarcinoma NOc z2 CAT25 40 3 BHEEJeRIAK BOO d 5 LCS RBLECT B 9 DRADD 3 PET 4a MRI T 4D PET E BR RE CD SHE M 60 2 PET 5a amp n Bqbb 5c 5d
131. G009 29 195 235 500mL 0 1 1 e E PET CT 10 30 eb 307 RASUSS ERDER CHOOT ANLC Rak CBIERES S cc O
132. Vinili iiid PPP classV 1s MIPIE Ga PET CT CES eb SUVmax 9 1 Ga MIP FDG t S HE 82c Grade SHH ORRE E RZEROORE A SES C p 2 o ASm ae OU YER DO KSHBEOJCODICERD TACAR ESN THSF EK FDG GDp PET CT ha P a E i i A TNI is dra c qug au A I E 9 gl LL Jimi ner PR E Ue Mero UE ru 1 e Desa x 4 t a E M p f 1 k TAUT Shi L LLIS SH ri AEA lu d jt 2 E Tf as KC b p l P YEN ia 1 4 mL g p F Me i Tp 1 E o E uli a o a u ld 3 Jh xul ro An D ODIT ae e b apr M amp n s B La j C I SE aum it rd ua FT a amp w Cad n Ati T
133. 2a FDG PET PET FDG 2b Ga CT GD PET 2c E RUBBER OO SEA 50 TUBE CT C 3a 3c PET PET PE T FDG GD Ha CT 3D PET 3c PET 60 PET CT cTPN3GM 1 PET PET CT MIP
134. FDG Gamut of FDG PET BISER PER GRAE RRE BAI BR WS N mata KELIR ika Ee AORO
135. Li PET PET PET PET 1 2 FDG SUV Standardized Uptake Value 3 background FDG PET 1cm 5cm FDC FDG FDG PET FDG FDG TUERI pap Bm ERI tub tuD FR porl
136. PET S004 PET 005 FDG PET PET PET 10 006 eerenossamnnoms k 1 1 PET 1 2 PET 1 PET PET PE
137. c PET PET 3 PET a PET b FDG PET kc 1 PE 150mg dL 150mg dL PET PET 1 FDG 3 FDG
138. CT GS KRAO MRI FDG T PET CT PET PET 1 Petrowsky H et al Impact of integrated positron emission tomography and computed tomography on staging and management of gallbladder cancer and cholangiocarcinoma J Hepatol 2006 Jul 45 1 43 50 2 Koh T et al Differential diagnosis of gallbladder cancer using positron emissio
139. PET FDG 4 PET staging por2 FDG PET
140. por Sig muc aE Q ENROSBEI FDOSERIIE EE 1 N FDG CT NEE Dis SUV 0 7 6 SUV N FDG FDG T N PETICd PES CAR U CT 1cm SUV
141. 4a PET CT 4b PET CT 4c 4d FDG 4e FDG 4b PET si a F Me e 4a MIP 4d PET 4e fe PET 80 1 5 1 OGy 4 CT 5a PET MIP
142. PET CT PET C PET CT TNM TEI CRI SS UT UD FDG PET PET CT FDG
143. PET CT me 1 5TBq F 18 7 PET SPECT 5 FDG 6
144. PET CT EE CT PET CT Ulo AD WORRIE E UC BUR EROR Ge OO ERE 9 10 CT CT HRCT 9a MIP 9b CT PET CT 9c CT PET CT 60 CT4N 1MO CRT41Gy RT20Gy 1 SUVmax 5 8 viability
145. 2007 27 425 456 Bq D Ba CCF D Ba P mL R cps pixel PET XCCF Bq mL PET mL P mL ROI cps pixel R cps pixel EA 7 PET JESHA X 0073 C2008 2008 8 FDG PET CT 2009 29 2 195 235 9 Ver 1 008 64 8 1015 1018 10 http Wwwjjira net OrJp anzenkanri 01_hoshutenken 01 OS html 11 C PET JESRA 11 0001 A2OO9 2009 12 PET quact 2012 13 PET 2006 1 PE
146. Castleman G CSF G CSF 1 PET 7 2 X EPEEBBC ITALO BS PET
147. FDG CEA 6b c ZN AWR EDRN E Mea Y PET CT Es y 6a MIP 6b PET 6c PET L 6d MIP 6e PET 6f PET 60 PET CTpefT BEH 200 PET MIP 7Za FDG 7b 7Zc FDG 7d 7a MIP 7c CT 7e 1 53 8 596 PET CT
148. MRI X CT PET CT FDG lcm FDG DCIS MMG US MRHI CT PET CT FDG
149. hot spot 3 CEA17 G3 CA198 9 511 6 5a MIP CA1285 3211 9 4 serous cystadenocarcinoma with clear cell adenocarcinomatous component FDG CT PE bb PET CT bc PET CT 5d PET CT PET 1 60 serous 1cm cystadenocarcinoma 3
150. micrometastases 179 7218 31 7 115 369 5mm 40 1196 g0 796 1 cm PET CT micrometastases TOF time of flight TOF 5mm TOF PET CT 5
151. FDG BZ PET C CT 1 PET CT 3 FDG PET 4 FDG PET CT PET CT Fi SHE RI FDG FDG PET CT PE es FDG FDG PET RIFE RTIEUSE RTEA d RT S8 RI
152. PE PE PET PET PET jn vivo RECIST Response Evaluation Criteria in Solid Tumors PET RESIA metabolic responder non responder PET PERCIST PET Response Criteria in Solid Tumors metabolic tumor volume total lesion glycolysis
153. PET EUS EUS CT PET EUS CT PET 8096 509 57 Z096 8396 8596 Coa micrometastases PET CT 006 Yuan S 83 99 8 19 PE Kato H 46 09 99 496 Okada M 60 096 G39 596 PET 6 7mm PET
154. SUV 6 1 CT MRI PET PET G09 PET C CT
155. US CT CT MRHI PET PET PET viaDility PET
156. FDG PET MRI 4 PET l Lynch CF et al Urinary system Cancer 1995 75 1suppl 3 16 329 2 Habuchi T Origin of multifocal carcinomas of the bladder and upper urinary tract molecular analysis and clinical implications Int J Urol 2005 12 8 709 716 3 Vikram R et al Imaging and staging of transitional cell carcinoma part 1 lower urinary tract AJR Am J Roentgenol 2009 192 6 1481 1487 4 Sch der H et al Positron emission
157. FDG PET CT PET CT FDG CT JIRKY PTP RIZ FBA BR AIR PET FDG FDG FDG PET CT COT t 4f PET 50 TEHEC Fasi BB ESWUER BRNU 77 EA MRI
158. adenocarcinoma PET 65X50mm SUVmax 9 9 3Db FSERB RIS EATE Y RE ESRB A ODBTPHRSBT PARE ESTER 3a CT PET 63 196 G1 9 2 4 396 unen CT MRI FDG
159. pSS 251 pN1 CT PET CT PET CT 2a c FDG SUVmax 9 14 2a MIP PET 9 itas 3 55 fur 0D B 788 0D 3183 Ha fl D te T cx N PS EE RB S e BJ IC tubular adenocarcinoma CT PET CT PET CT GD PET CT Gc CT 60 3
160. CT 4a 4b 4c PET FDG 4d 4e DLBCL 4a CT 4D CT 4d PET CT 4e PET PET PET 4f FDG PE
161. PET le PET CT 18 Ds PET 24 PET 27 PET 32 PET 40 PET 48 PET 54 PET 60 PET 69 PET 73 PET 80 PET 86 PET 91 PET 97 PET 103 PET 112 FDG EE FDG F FDG PET FDG PET FDG 005 8 S013 10
162. US MRI PET CT FDG xc WEE JV PET CT 80 100 50 979 IIB A 139 NG 1 4 5296 TIE MRI CT
163. 5 159 CT 10 096 3 PET FDG FDG IWC 2012 PET PET CT PET CT HL 8596 NHL 409
164. k HS 5T RESR MORTAS eril e C D C c PET PET CT Er ICRP Publication105 ICRP 1990 2007 3 3
165. 5b P 1 P ti k unco NE S B meu T t 5a CT 5D MIP FDG 5c 5d 5e FDG T PET CT 5c PET 5d PET 5e PET PET 60 PET MIP 6d PET 6e 6e f PET CT MIP 6a PET CT FDG ARBOR 6b
166. 6c PET CT PET PET CT 7b PET CT 7a MIP 7c PET CT 7d PET CT F3 fes irte CD STRE S SE tub2 WEDYARAX A8a VARTREE 8b c PET CT 5FU CDDP CH Ba BARRER 8Bb MIP 8c PET CT PENEKANAN EDERA zT X PET modality PET CT CT 3D CT colonography
167. FDG FDG 5 PET 159 CT MRI PET
168. PET FDGC FDG 5a c ns ER 5d e PET PET MRI 2 MRI PET AP 15a MIPIBIR l 5D CT 5d MRI PET PET PET
169. Rb tuDular adenocarcinoma pSM 251 pN1 1 PET CT 1 PET CT 1 3a focal FDG GUVmax 3 7 eft MHI GD Ue SOBRE RIZ OCT 1 T ADC 9x3 tuDular adenocarcinoma 1 PET CT PET CT 3c CT 1 09 focalkFDOo amp f ld SUVmax 3 0dc x ab 2Wrl CERES 6 ccD PET
170. 1b CT le PET CT FDG SUV PET lc CT 60 10 744 7ng mL lt 20ng mL CT
171. 4 44 496 Do 6 5a CT 4 bb PET CT PET 60 S6 6a b Do MABE mao CHERT MALTU V YE 6a MRIT 5 159 CT MRI PET
172. N RELEE a CMN REVU V Aimed PET C CT FDG CERES 50 4 PET CT FDG 247 6MBda 4 65MBq Kg 71mg mL PET CT MIP 5a FDG SUVmax E 4 3 D 3 9 Md qM 1 5
173. e CT CA 19 9 6296 89796 196 10096 38 PET T 1 e FDG 150mg dL e
174. 1 7 400mm X300mm X300mm 60 7Okg PET CT 1 8 FDG PET PET CT RARI OEDD JHI ZEANI ARE 1 1 1 3 PET CT EOIR FDG PE FDG PET CT k PE PET CT
175. PET CD20 Y 90 ibritumomab tiuxetan Zevalin FDG avid MHRI HL NHL 709 PET CT CT FDG RDU IIF PARIU YVER BARIERE WEIR
176. 2cm FDG 2 cm 10096 e PEESVLURTERS T f DE SR Ben e 78 C 00 S a t PS CC ua e CT e eCA19 9 CT MRI PET EL HER ODFDG SERS e NIAI OD 8Z Bro OD 9 2 8 UY UY SEED D S09 6 7mm
177. 5 30OkBa ml G 2 65kBa ml 10 4 6 8 min 6 8 min PET ELC IO T9 TZ 88 989 9 ITIT 4 1 30 RC recovery coefficient HOI 3 mm 4 1 33kBq mL PET QH 10mm N10mm 30 PET NECphantom gt 10 4 Mcounts N10mm 6 2 96 QH 10mm N10mm 1 9 96 gt 0 38 0 38 10mm 2 2
178. 6 007 54 501 514 TOINI PETRAAA E 1 PET FDG 1 5MBq Kg 3GD 2 PET a FDG 4 6 b PET c FDG 4 PET a PET FDG b PET
179. B 17Tmm PET CT lc MMG MLO 40 PET CT FDG 303MBq 5 92MBq Kg 84mg mL MIP 2a FDG FDG NG3c PET CT E b SUVmax E 8 5 D 9 6 GUVmax E 64 D 66 SUVmax
180. 24 m C ER DL m gt PET SUV Keyes JW Jr 1995 JNM Silly Useless Value PET PE
181. 4 5 50 3 CT PET PET CT 4 4 30mg 1 PET 30 PET CT MINON med Pnus cs f 136 0075 3 4 10 g 2013 41 E FX TEL 03 5634 7006 TA 1304 G02 http www nmp co jp
182. 84mg mL MIP Ga FDG MIP 3b FDG PET CT 3c FDG GUVmax E 14 1 D TS5 8 SR TRAE FDG SUVmax E 3 0 D 3 6 MRHI 3d 1 PET CT 3D MIP 10 SAORI a ni NR PET CT a SUVmax
183. DO amp A TERSSETRS 4c 4a Caggressive tyDe 4b v vE a Elda 4b 4c BiU 5cm PET CT cm tuD 5a b EU m F w 5a MIP 5D PET CT 10cm 6a Cc muc gt tubD tub1 gt pap PET CT 6b PET CT e Y 6a MIP
184. PET 57 9896 97 1009 6 PSA 3 196 PSA 7596 10096 mTc MDP PET 189 33TTc MDP 9496 gt PET 77 33mTc MDP PSA 6 PET PET 3 PET SUVmax 1 6 04 RAKCI 648 2960 UY2 si FDG
185. RI RI RI PET CT 1 PET CT
186. RI PET RI 2 HEPA HRI 3 HRI HI 6 4 PE T RI
187. TO medir anes Eb Ec e mxkXaFDGl amp FDG PETDVIRISoSFHC TUCSOO2tED531F60 eOObsEI Sie KR C Tl C ANDRA Re Uc C flcd D UV ZU FUIZZRHESTE FDG PET PET 0193 170 PE PET PET PET CT PET CT PET PET PET PET PE PET
188. 0mloo JM 31 4a MIP SUVmax BUE KruskaLWallis p lt 0 001 Tla Tlb T2 T3 4 ees nt MS Eleg SGUVmax 45 PET CT 4c PET CT 60 SM Ad PET SUVmax 3 6 SUVmax 10 0 FDG
189. 1 PET CT PET CT FDG ignem Kato 32 PET T1a M1 M2 M3 189 T1Db SM 1 SM 50 coco its ccelis des SUVmax 4 1 T3 AD 1009 Pb PET CT n ZW 1
190. 2 PET PET PET PET FDG PET PET PET 1 4 PET PE FDG PET
191. 50 e 16 8 1 0801001 1 7 6 1 0601006 19 3 30 0330010 PET FDG PET OOS 2005 ep FDG PET 2008 2008 2006 ICRP Publication 103 P007 C009 ICRP Publication 105 G01 13 14 006
192. 7 EO 0 6 TNM T TNM NN TNM M T M1 NO duo EBERT Tla M2 NI 1 2 IN jn PETESM M3 N2 R i SM1 SULBERS o UT PER 2012 4 PET PET 3 PET SUVmax cC EZ 3 4 EUS PET PET M1 SM 1 SM
193. IIB or IIA breast cancer a prospective study J Nucl Med 201 1 52 10 1526 1534 5 Groheux D et al F FDG PET CT in staging patients with locally PET advanced or inflammatory breast cancer comparison to conventional staging J Nucl Med 2013 54 1 5 11 6 Avril N et al Response to therapy in breast cancer J Nucl Med 2009 50 5 suppl 558 638 60 PET CT FDGi25 s 263 7MBq 4 35MBq Kg 101mg mL FDG 1 E D MIP 1a FDG PET CT 1b 12mm FDG SGUVmax d FE Jl e 1a MIP lb PET CT 1d MRI E 5 9 D 7 MLO 1c MRI 1d
194. Impact of positron emission tomography computed tomography surveillance at 12 and 24 months for detecting head and neck cancer recurrence Cancer 2012 Dec 7 doi 10 1002 oncr 2 892 Epub ahead of print Kang KW et al Prevalence and risk of cancer of focal thyroid incidentaloma identified by 8E fluorodeoxyglucose positron emission tomography for metastasis evaluation and cancer screening in healthy subjects J Clin Endocrinol Metab 2003 88 9 4100 4 104 la MIP 8 Hany TF et al Brown adipose tissue a factor to consider in symmetrical tracer uptake in the neck and upper chest region Eur J Nucl Med Mol Imaging 2002 29 10 1393 1398 9 Nakasone Y et al The role of whole body FDG PET in preoperative assessment of tumor staging in oral cancers Ann Nucl Med 2001 15 505 512 10 Stokkel MP et al 18E fluorodeoxyglucose dual head positron emission tomography as a procedure for detecting simultaneous primary tumors in cases of head and neck cancer Cancer 1999 86 2370 2377 1 1 Lonneux M et al Positron emission tomography with fluorodeoxyglucose for suspected head and neck tumor recurrence in the symptomatic patient Laryngoscope 2000 1 10 1493 1497 1b PET CT 12 Regelink G et al Detection of unknown primary tumors and distant metastases in patients with cervical metastases value of FDG PET versus conventional modalities Eur J Nucl Med EM FD
195. OSEDTUC PET CT GEF 10096 c BF GE 98 19 6 PET PET CT PET 8 8a Bb PET CT HE 60 5 6 SPECT PET CT 1Z
196. Y i T TN ay Fr j ka ox gp is Ere Ro Nga how hi Ps a n i at dto Uu RS i kf i m hm L 1 ta y i sil 4 F r4 FL NIR S P T li f M M Gum C MP ME VE Bt T a w ei om E LA rS DNE nde e T rg T bs 07 e TO A RAS i e es Ar arid c HERE SOmWdV HUE HIE class ibt CT 3a PET CT 3b PET CT 3c 3a CT SUVmax 18 3a CT 3b PET CT 3C PET CT 3e MIP 3d CES Cels TU CREER COSE SS SED ER C e RRE o HE de
197. a review Ann Surg Oncol 201 1 18 3338 3352 6 van Vliet EPM et al Staging investigations for oesophageal cancer a meta analysis Br J Cancer 2008 98 547 557 7 Yuan S et al Additional value of PET CT over PET in assessment of locoregional lymph nodes in thoracic esophageal squamous cell cancer J Nucl Med 2006 47 1255 1259 8 Kato H et al The additional value of integrated PET CT over PET in initial lymph node staging of esophageal cancer Oncol Rep 2008 20 857 862 9 Okada M et al Integrated FDG PET CT compared with intravenous contrast enhanced CT for evaluation of metastatic regional lymph nodes in patients with resectable early stage esophageal cancer Ann Nucl Med 2008 23 73 80 10 AHA F CT 1997 57 391 394 1 1 Schr d r W et al Lymph node staging of esophageal squamous cell carcinoma in patients with and without neoadjuvant radiochemotherapy World J Surg 2002 26 584 587 12 Conti M et al First experimental results of time of flight reconstruction on an LSO PET scanner Phys Med Biol 2005 50 4507 4526 13 TOF time of flight PET SNR INNERVISION 2010 85 128 35 39 14 Werner MK et al Respiratory gating enhances imaging of pulmonary nodules and measurement of tracer
198. 2 deoxy D glucose PET in detection of pancreatic cancer value of quantitative image interpretation Radiology 1995 195 339 344 13 Zimny M et al Fluorine 18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma a report of 106 cases Eur J Nucl Med 1997 24 678 6828 14 Higashi T et al Diagnosis of pancreatic cancer using fluorine 18 fluorodeoxyglucose positron emission tomography FDG PET PET usefulness and limitations in clinical reality Ann Nucl Med 2003 17 261 279 15 Nakamoto Y et al FDG PET of autoimmune related pancreatitis preliminary results Eur J Nucl Med 2000 27 1835 1838 PET TE GUVmax 6 0 8 6 Hla MIP Virchow 1a c 1b CT lc PET CT 68 CA19 9 1600 ga c
199. 7 UJAU eTUcCcPb TU PET 2013 PE FDG PET 10 PET FDG PET PET FDG 1 PET nere L a c PET FDG PET CT PET CT
200. MRI PET C modality PET CT PET CT PET FDG CT modality
201. PSA7 08 ng mL BCG ESODSZEETDVSEOTUCe E 7a PET CT PET CT 7a SUVmax 8 HE Zb 7b HE PET o 1 PET BIRD UE
202. SCOT A IEERODIA T O A PET PE CT FDG 1 Cistaro A et al Assessment of a new F FDG PET CT protocol in the staging of oral cavity carcinomas J Nucl Med Technol 2801 1 Mar 39 1 7 13 2 Matthews R et al Head and neck cancers post therapy changes in muscles with FDG PET CT Clin Nucl Med 2010 Jul 35 7 494 498 3 Partridge M et al Technical note 9 month repositioning accuracy for functional response assessment in head and neck chemoradiotherapy Br J Radiol 2012 Dec 85 1020 1576 1580 4 Yoo J et al Evidence based guideline recommendations on the use of positron emission tomography imaging in head and neck cancer Clin Oncol R Coll Radiol 2012 Sep 25 pii S0936 6555 12 00851 8 5 Newbold K et al PET CT in radiotherapy planning for head and neck cancer Front Oncol 2012 2 189 6 Ho AS et al
203. uptake in FDG PET CT AJR Am J Roentgenol 2009 193 1640 1645 15 Chatterton BE et al Positron emission tomography changes management and prognostic stratification in patients with oesophageal cancer results of a multicentre prospective study Eur J Nucl Med Mol Imaging 2009 36 354 361 16 Gilies RS et al Additional benefit of F fluorodeoxyglucose integrated positron emission tomography computed tomography in the staging of oesophageal cancer Eur Radiol 201 1 21 274 280 17 Teyton P et al Use of positron emission tomography in surgery follow up of esophageal cancer J Gastrointest Surg 2009 13 451 458 18 z lker T et al Comparison of F FDG PET CT with To MDP bone scintigraphy for the detection of bone metastases in cancer patients Nucl Med Commun 2010 31 597 603 PET PET PET PET 10
204. 3 FDG 18 FDG FDG CH20H CH20H Xd 2 FPE 2 OH H OH OH H S OH OH H OH H 18F FDG we FDG _ PET FDG FDG FDG FDG 6 FDG 6 FDG 6 metabolic trapping 4 FDG
205. 9kg 7102 ESTE VATI 50kg 62kg 74kg Dou 1 85MBq 46kg 58kg Okg IO 74MBq 44kg 55kg 65kg 207 163MBq 41kg 1Kg 61kg S 15GMBq 38kg 48kg 58kg 405 144MBq 36kg 45kg 54kg 507 1G5MBq 34kg 42kg 5lkg 6045 127MBq 32kg 39kg 47kg ZOJ 19MBq 30kg 37kg 45kg 807 12MBq eakg 35kg 42kg oo 105MBq 26kg 33kg 40kg 00 L AIAHOV WLO Ife 135 1898 J 20 135 150 165 S bgIWNZ MBq kg sec bed PET CT D Ofsfsoktt exer KOO PET CT RE E ORIZRIF SN IU TO ON OO T50 120 30 1 20sec bed WE CRAH ER PET CT 144x144 128x188 168x168 128x188 144x144 128x188 2E PET PET CT PET CT F PET CT F 80sec bed Gaussian mm BRUM OU 3D OSEM OSEM OSEM OSEM RAMLA OSEM PET CT RE z 9s VE CT ZR MEI EL agam imd dm LUUOVYF V I PIRTIN S N signal to noise ratio TOF time of flight G8
206. CT EN suere Xil S7 SUVmax MRI 46 S5 6 SUVmax 4 3 FDG eia PET CT CT CT PET CT 1 PET CT s A a d V T Si s XI 3c MIP PET CT CT FS T2 ADC map 3b MRI z UJ U PETORIBEC ES PET cds ETHER FDG SUV
207. E 4 2 D 53 WM 2a MIP 19 c MRI FDG MRI 2c 6 MRI PET CT GD PET CT PET 50 PET CT FDG 199MBq 3 34MBq Kg
208. G Mol Imaging 2002 29 1024 1030 185 i 13 Bannas P et al Can F FDG PET CT be generally recommended MIP PET CT in patients with differentiated thyroid carcinoma and elevated z SA TN E thyroglobulin levels but negative 131 whole body scan Ann FDG Nucl Med 2012 26 1 77 85 HIKO S ERTRANOFDGOSHRUUEDERERCTUV PET CEREO U Y VES T2 Dt Ha C SR RIS G8m amp Bl 8Ol1 F5Ha D eI 7 A BRAETUD rH PREBESCODEEHRCOO ISC HZft74 ZBSRELe S 82 EICCeO011 F8H d amp ZE FUERINT 2O12 E8H MRI FI CEARA Palo U CO 7xREXTU fe sz BIST HERI C mi FEEBS C SZ T UC T 27x 18mm Ga PET C CT FDG GD FDCG DIMIC PFsREICSERRD ERE L PSREDSORID SEDTUO 2a CT Gd GD PET CT MIF
209. Hodgkin s Iymphomas Radiol Clin North Am 2004 42 1083 1 1 OO 12 Zijlstra JM et al E fluoro deoxyglucose positron emission tomography for post treatment evaluation of malignant lymphoma a systemic review Haematologica 2006 91 522 529 13 Zinzani PL et al Early interim F FDG PET in Hodgkin s lymphoma evaluation on 304 patients Eur J Nucl Med Mol Imaging 2012 39 4 12 14 Itti E et al Prognostic value of interim PF FDG PET in patients with diffuse large B Cell lymphoma SUV based assessment at 4 cycles of chemotherapy J Nucl Med 2009 50 527 533 y BIBzIe KO EE DORA BIE AUA mO C ELESMINIA RI ESE PET Ckm CERS RRS RAE 1a 1b FDG CRH 1c la PET lb PET CT DLBCL PET
210. Sv 500mSv 4 1 1 EU ERE 18v Q 30 27 4 4 250 Sv 93 1 1mSv 11 16 PET CT GD 3 1 1 5
211. T 20 409 5 1 HG PET 88 096 36 196 C 82 796 84 19 PET CT 31 69 MocLeish AR CT 4 PET 11 5 8
212. T CT MRI S013 4 A E PET FDG FDG PET PET FDG PET CT PET CT PET CT PET CT PET PE C PET PET E Ee FDG 4 PET 6 PET 11
213. T PET PET PET PET PET 2 PET PET PET PET PET PET 3 1
214. T CT PET CT 1a c 4cm FDG GUVmax FDG 18 5 PET CT FDG SUVmax 11 0 PET CT OFIAR PET CT 60 Ra tuDular adenocarcinoma
215. cta Oncol 2002 41 5 425 429 10 Jana S et al Nuclear medicine studies of the prostate testes and bladder Semin Nucl Med 2006 36 51 72 1 Shvarts O et al Positron emission tomography in urologic oncology Cancer Control 2002 9 335 342 12 Oyama N et al FDG PET for evaluating the change of glucose metabolism in prostate cancer after androgen ablation Nucl Med Commun 2001 22 963 969 _ ZUINU PETORHE C En 80 PSA9 5ng mL MIP 5a PET C CT 5b C SUVmax 16 5a MIP 5d 5d HE 5e Gleason sc
216. gement of colorectal liver metastases Cancer 2005 104 2658 2670 10 McLeish AR et al Impact of PF FDG PET in decision making for liver metastectomy of colorectal cancer ANZ J Surg 2012 82 30 35 1 1 Metser U et al PET CT of extranodal lymphoma AJR Am J Roentgenol 2004 182 1579 1586 12 Lee WK et al Abdominal manifestations of extranodal lymphoma spectrum of imaging findings AJR Am J Roentgenol 2008 191 198 206 80 CT IPMN 1a b c CT HCC IPMN PET CT 1 SUVmax 3 3 GUVmax 2 8 1d e IPMN IPMN ld PET CT
217. lesion characterization AJR Am J Roentgenol 2010 194 31 1 321 5 Kuyumcuoglu U et al F FDG PET CT and USG CT in benign and malignant ovarian tumors with postoperative histopathological correlation Ginekol Pol 201 1 82 602 608 6 Fuccio C et al Noninvasive and invasive staging of ovarian cancer review of the literature Clin Nucl Med 201 1 36 889 893 7 Kumar Dhingra V et al Impact of FDG PET and PET CT imaging in the clinical decision making of ovarian carcinoma an evidence based approach Womens Health Lond Engl 2012 8 191 203 8 Antunovic L et al Revisiting the clinical value of F FDG PET CT in detection of recurrent epithelial ovarian carcinomas correlation with histology serum CA 1285 assay and conventional radiological modalities Clin Nucl Med 20128 37 e184 188 9 Son H et al Role of FDG PET CT in staging of recurrent ovarian cancer Radiographics 201 1 31 569 583 PET OE TS ELU TO BICI S REII 1 50 REES Ab 1 2 MRI 13mm
218. lse negative and false positive lymph node staging with positron emission tomography in patients with lung cancer J Thorac Cardiovasc Surg 2004 127 1087 1092 5 Qu X et al A meta analysis of FDG PET CT FDG PET MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer Eur J Radiol 2012 81 1007 1015 60 PE PET FDG 1a la PET lb CT C 1b 509 1c d Tw o a cert a ua DE E 0 c rt CT CT
219. mm PET r FDG FDG FDG FDG pyometria 1 8g CBR PET CT MEDICAL VIEW 2010 PET a012 28 919 925 3 Kitajima K et al Performance of integrated FDG PET contrast enhanced CT in the diagnosis of recurrent uterine cancer compariso
220. n tomography with fluorine 18 labeled fluoro deoxyglucose FDG PET J Surg Oncol 2003 Oct 84 9 74 81 3 Ramos Font C et al Positron tomography with 18F fluorodeoxyglucose in the preoperative evaluation of gallbladder lesions suspicious of malignancy Diagnostic utility and clinical impact Rev Esp Med Nucl 201 1 Sep Oct 30 5 267 275 4 Rodriguez Fern ndez A et al Positron emission tomography with fluorine 18 fluoro 2 deoxy D glucose for gallbladder cancer diagnosis Am J Surg 2004 Aug 188 2 171 175 5 Kitazono MT et al PET imaging of acute cholecystitis Clin Nucl Med 2006 Jan 31 1 23 24 6 Maldjian PD et al Adenomyomatosis of the gallbladder another cause for a hot gallbladder on F FDG PET AJR Am J Roentgenol 2007 Jul 189 1 W36 38 7 Kim YJ et al Usefulness of F FDG PET in intrahepatic cholangiocarcinoma Eur J Nucl Med Mol Imaging 2003 Nov 3GOCHIS 1467 T4 78 8 Ruys AT et al FDG positron emission tomography computed tomography and standardized uptake value in the primary diagnosis and staging of hilar cholangiocarcinoma HPB Oxford 2011 Apr 13 4 256 262 9 Li J et al Preoperative assessment of hilar cholangiocarcinoma by dual modality PET CT J Surg Oncol 2008 Nov 1 98 6 438 443 10 Kluge R et al Positron emission tomography with F fluoro 2 deoxy D glucose for diagnosis and staging of bile duct cancer Hepatology 2001 May 33 5 1029 1035 1 1 Kim JY et al Clinical
221. n with PET and enhanced CT Eur J Nucl Med Mol Imaging 2009 36 362 3 l 4 Chung HH et al Clinical impact of integrated PET CT on the management of suspected cervical cancer recurrence Gynecol Oncol 2007 104 529 534 5 Kitajima K et al Performance of FDG PET CT for diagnosis of recurrent uterine cervical cancer Eur Radiol 2008 18 2040 2047 6 Chung HH et al The clinical impact of F FDG PET CT for the management of recurrent endometrial cancer correlation with clinical and histological findings Eur J Nucl Med Mol Imaging 2008 35 1081 1088 7 Park JY et al Clinical impact of positron emission tomography or positron emission tomography computed tomography in the posttherapy surveillance of endometrial carcinoma evaluation of 88 patients Int J Gynecol Cancer 2008 18 1332 1338 8 Sharma P et al Carcinoma endometrium role of 18 FDG PET CT for detection of suspected recurrence Clin Nucl Med 2012 37 649 655 9 Picchio M et al High grade endometrial cancer value of F FDG PET CT in preoperative staging Nucl Med Commun 2010 31 506 512 FDG RRHH PE T
222. ns Gastroenterol Clin Biol 2010 34 8 9 465 474 4 Kato T et al Fluorodeoxyslucose positron emission tomography in pancreatic cancer an unsolved problem Eur J Nucl Med 1995 22 32 39 5 FE Bm PET 2001 176 184 6 Sperti C et al Value of 18 fluorodeoxyglucose positron emission tomography in the management of patients with cystic tumors of the pancreas Ann Surg 2001 234 675 680 Nakamoto Y et al Evaluation of pancreatic islet cell tumors by fluorine 18 fluorodeoxyglucose positron emission tomography comparison with other modalities Clin Nucl Med 2000 25 115 9 8 Fr hlich A et al Detection of liver metastases from pancreatic cancer using FDG PET J Nucl Med 1999 40 250 255 9 Bang S et al The clinical usefulness of 18 fluorodeoxyglucose positron emission tomography in the differential diagnosis staging and response evaluation after concurrent chemoradiotherapy for pancreatic cancer J Clin Gastroenterol 2006 40 923 929 1O Higashi T et al Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET J Nucl Med 1999 40 1424 33 1 1 Nakamoto Y et al Delayed F fluoro 2 deoxy D glucose positron emission tomography scan for differentiation between malignant and benign lesions in the pancreas Cancer 2000 89 2547 2554 12 Stollfuss JC et al 2 fluororine 18 fluoro
223. ore 44 5 9 5D PET CT bc PET CT CX Quer a T UD EX Fern i aik PASE i xd 4d o i X SN Hrs XA S QE EE Fi E 70 PSA 6 PSA PSA11 55ng mL 24 85ng mL 1 33 23ng mL Gleason score 44 5 9 MIP 6a 6a MIP 6c PET CT PET CT 6b SUVma
224. role of F FDG PET CT in suspected and potentially operable cholangiocarcinoma a prospective study compared with conventional imaging Am J Gastroenterol 2008 May 103 5 1145 1151 12 Fritscher Ravens A et al FDG PET in the diagnosis of hilar cholangiocarcinoma Nucl Med Commun 2001 Dec 22 12 12877 12885 13 BHHBESERSIC BID AG PETzZWITOUSSR 2006 503 148 153 14 Kumar R et al Role of 18F FDG PET CT in detecting recurrent gallbladder carcinoma Clin Nucl Med 2012 May 37 5 431 435 15 FDG PET 5009 23 5 775 782 o HERE E EDIEN 75 1 CT BA Berc n EBEEDESAC PET OCT e PET SUVmax 5 55 PET CT 1a d 3 PET C CT 1e lb PET le CT
225. s cystadenoma s Bo ERE OD OD T6 STER A C58 U YDG SETRED S les 08 d seid ER C p D BHO De SETERS BI FDG gt E i FDG PET PET CT FDGC CT MRI PET FDG FDG
226. tomography for prostate bladder and renal cancer Semin Nucl Med 2004 34 274 292 5 Drieskens O et al FDG PET for preoperative staging of bladder cancer Eur J Nucl Med Mol Imaging 2005 32 1418 141 7 6 Jadvar H et al F 18 fluorodeoxyglucose PET and PET CT in diagnostic imaging evaluation of locally recurrent and metastatic bladder transitional cell carcinoma Int J Clin Oncol 2008 13 42 47 7 Patil VV et al F FDG PET CT of transitional cell carcinoma AJR Am J Roentgenol 2009 193 WA9 7 504 8 ft FDG PET CT 20128 57 12 1697 1702 9 Liu IJ et al Evaluation of fluorodeoxyglucose positron emission tomography imaging in metastatic transitional cell carcinoma with and without prior chemotherapy Urol Int 2006 77 69 75 10 Anjos DA et al F FDG PET CT delayed images after diuretic for restaging invasive bladder cancer J Nucl Med 2007 48 64 O 11 Palou J et al Urothelial cell carcinoma in upper urinary tract role of PET Imaging Imaging in Oncological Urology opringer 2009 p 155 160 1 2 Harkirat S et al Forced diuresis and dual phase 8E fluorodeoxyglucose PET CT scan for restaging of urinary bladder cancers Indian J Radiol Imaging 2010 20 1 13 19 PET 0
227. x 5 d PET CT JS TA Pri e CI c PET CT 6d GRE 6Ob PET CT c E Ww av ES J m d dl 6d PET CT PET 70 4 1 BCC PET CT
228. ystematic review Blood 2008 11 1 504 5198 3 Weiler Sagie M et al F FDG avidity in lymphoma readdressed a study of 766 patients J Nucl Med 2010 51 25 30 4 XE CO011 820 825 5 Muslimani AA et al The utility of 18 F fluorodeoxyglucose positron emission tomography in evaluation of bone marrow involvement by non Hodgkin lymphoma Am J Clin Oncol 2008 31 409 412 6 Pelosi E et al FDG PET in the detection of bone marrow disease in Hodgkin s disease and aggressive non Hodgkin s lymphoma and its impact on clinical management Q J Nucl Med Mol Imaging 2008 52 9 16 FDG PET CT 1 011 32 1 7 18 8 Baba S et al Impact of FDG PET CT in the management of lymphoma Ann Nucl Med 201 1 25 701 716 9 Juweid ME et al Use of positron emission tomography for response assessment of lymphoma consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 2007 85 571 578 10 Cheson BD et al Revised response criteria for malignant lymphoma J Clin Oncol 2007 85 579 586 1 Kumar R et al Utility of fluorodeoxyglucose PET imaging in the managementof patients with Hodgkin s and non
Download Pdf Manuals
Related Search
Related Contents
Tecnostyl ACR012 Étiquette ( PDF, 44 KB) - Better Pest Control VGN-FW490DAB DL CTM Zingueur Ferblantier 08 2012 And Yet Another One SRS SureCross DX70 Wireless Point-to-Point Kits EVM-91L30 Copyright © All rights reserved.